SciClone drug sustains swine flu shot in study

Mon, 02/08/2010 - 6:20am
The Associated Press

SciClone Pharmaceuticals said Monday that a second round of testing showed again that patients who used its vaccine booster combined with a swine flu vaccine had better resistance levels.

In January, SciClone first reported tests using its Zadaxin booster and Novartis AG's vaccine Focetria.

SciClone and its partner Sigma-Tau said an immune response was achieved in 93 percent of patients who received a low dose of Zadaxin and 94 percent of patients who received a bigger dose. That compares to 77 percent of patients who received only Focetria.

SciClone Pharmaceuticals Inc. said it will report more data from the study in about six months.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.